BioXcel Therapeutics, Inc. (NASDAQ: BTAI)

BioXcel Therapeutics, Inc. is a biopharmaceutical company that leverages artificial intelligence to develop transformative medicines in neuroscience and immuno oncology. The company’s wholly owned subsidiary, OnkosXcel Therapeutics, focuses on immuno oncology drug discovery, while its core neuroscience efforts center on repurposing existing compounds such as dexmedetomidine into new indications like agitation associated with psychiatric and neurodegenerative disorders. Its proprietary AI platform analyzes large datasets to identify novel therapeutic uses for approved drugs, aiming to reduce development costs and timelines.

The company generates revenue primarily from sales of its FDA approved product IGALMI®, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar disorder in adults. IGALMI® is distributed through established pharmaceutical channels to hospitals, clinics, and patients under the supervision of healthcare providers. In 2024 and 2025, net product sales were $2.3 million and $0.6 million, respectively, reflecting a commercial‑focused strategy that maintains market presence while conserving cash for continued clinical development.

The company operates through the following segments: Neuroscience and Immuno oncology.

• Neuroscience: This segment develops and commercializes drug candidates for agitation in psychiatric and neurodegenerative disorders, including the approved product IGALMI® and investigational formulations such as BXCL501 for Alzheimer’s related agitation, bipolar disorder, schizophrenia, and other stress related indications.

• Immuno oncology: Through its subsidiary OnkosXcel Therapeutics, this segment focuses on advancing BXCL701, an oral innate immune activator, as a potential therapy for aggressive cancers such as metastatic castration resistant prostate cancer, pancreatic cancer, and other solid and liquid tumors, often in combination with immune checkpoint inhibitors.

BioXcel Therapeutics holds a niche position in the biopharmaceutical industry by coupling AI driven drug repurposing with a focus on areas with high unmet medical need in neurology and oncology. While it competes with larger pharmaceutical companies that have greater financial and commercial resources, its differentiated approach using existing drugs and machine learning to identify new therapeutic uses offers potential advantages in development speed and cost efficiency. The company’s intellectual property portfolio, including multiple patents on its sublingual film formulation and combination therapies, further supports its competitive stance.

The company serves patients, healthcare providers, and institutional customers such as hospitals and clinics that treat agitation in schizophrenia, bipolar disorder, and Alzheimer’s dementia. In the immuno oncology arena, its prospective customers include oncologists and cancer treatment centers interested in novel immune modulating therapies for hard to treat tumors.